
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
157.9423
Open
154.740
VWAP
157.01
Vol
7.85M
Mkt Cap
378.48B
Low
154.500
Amount
1.23B
EV/EBITDA(TTM)
12.48
Total Shares
2.41B
EV
385.14B
EV/OCF(TTM)
15.54
P/S(TTM)
4.19
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
22.85B
+1.78%
2.680
-4.96%
23.10B
+2.8%
2.688
+11.06%
23.46B
+4.17%
2.484
+21.79%
Estimates Revision
The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 1.5% over the past three months. During the same period, the stock price has changed by 3.55%.
Revenue Estimates for FY2025
Revise Upward

+1.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+0.33%
In Past 3 Month
Stock Price
Go Up

+3.55%
In Past 3 Month
15 Analyst Rating

8.21% Upside
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 170.21 USD with a low forecast of 159.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
7 Hold
0 Sell
Moderate Buy

8.21% Upside
Current: 157.300

Low
159.00
Averages
170.21
High
185.00

8.21% Upside
Current: 157.300

Low
159.00
Averages
170.21
High
185.00
Barclays
Matt Miksic
Hold
Maintains
$166 → $165
2025-04-17
Reason
Barclays
Matt Miksic
Price Target
$166 → $165
2025-04-17
Maintains
Hold
Reason
Barclays lowered the firm's price target on Johnson & Johnson to $165 from $166 and keeps an Equal Weight rating on the shares following the Q1 report. The company reported strong Pharma results offset by slower growth in MedTech, driven primarily by a series of one-timers and prior year issues, the analyst tells investors in a research note. The firm says J&J maintained its 2025 outlook despite additional deal dilution and tariff impact.
RBC Capital
Shagun Singh
Buy
Reiterates
$181
2025-04-16
Reason
RBC Capital
Shagun Singh
Price Target
$181
2025-04-16
Reiterates
Buy
Reason
Morgan Stanley
Terence Flynn
Hold
Maintains
$164 → $169
2025-04-16
Reason
Morgan Stanley
Terence Flynn
Price Target
$164 → $169
2025-04-16
Maintains
Hold
Reason
Morgan Stanley raised the firm's price target on Johnson & Johnson to $164 from $163 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Raymond James
Jayson Bedford
Buy
Maintains
$162 → $164
2025-04-16
Reason
Raymond James
Jayson Bedford
Price Target
$162 → $164
2025-04-16
Maintains
Buy
Reason
Raymond James analyst Jayson Bedford lowered the firm's price target on Johnson & Johnson to $162 from $165 and keeps an Outperform rating on the shares ahead of quarterly results. While a portion of the tariff drama was dampened last Wednesday, the firm still expects Q1 MedTech earnings season to be eventful. The uncertainty tied to the impact of tariffs has tightened investment decisions, reduced the appetite for risk, and weighed on MedTech multiples. Based on Raymond James' math, the market is baking in an 8% cut to annual EPS for its large cap coverage. While the firm acknowledges a heightened level of uncertainty, its initial view is that this seems excessive.
Raymond James
Jayson Bedford
Buy
Maintains
$165 → $162
2025-04-14
Reason
Raymond James
Jayson Bedford
Price Target
$165 → $162
2025-04-14
Maintains
Buy
Reason
Raymond James analyst Jayson Bedford lowered the firm's price target on Johnson & Johnson to $162 from $165 and keeps an Outperform rating on the shares ahead of quarterly results. While a portion of the tariff drama was dampened last Wednesday, the firm still expects Q1 MedTech earnings season to be eventful. The uncertainty tied to the impact of tariffs has tightened investment decisions, reduced the appetite for risk, and weighed on MedTech multiples. Based on Raymond James' math, the market is baking in an 8% cut to annual EPS for its large cap coverage. While the firm acknowledges a heightened level of uncertainty, its initial view is that this seems excessive.
B of A Securities
Tim Anderson
Hold
Maintains
$171 → $159
2025-04-10
Reason
B of A Securities
Tim Anderson
Price Target
$171 → $159
2025-04-10
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 14.91, compared to its 5-year average forward P/E of 16.36. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
16.36
Current PE
14.91
Overvalued PE
17.53
Undervalued PE
15.18
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
13.05
Current EV/EBITDA
11.67
Overvalued EV/EBITDA
13.85
Undervalued EV/EBITDA
12.25
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
4.51
Current PS
4.03
Overvalued PS
4.82
Undervalued PS
4.19
Financials
Annual
Quarterly
FY2025Q1
YoY :
+2.39%
21.89B
Total Revenue
FY2025Q1
YoY :
+2.81%
6.66B
Operating Profit
FY2025Q1
YoY :
+237.91%
11.00B
Net Income after Tax
FY2025Q1
YoY :
+238.81%
4.54
EPS - Diluted
FY2025Q1
YoY :
+18.56%
3.38B
Free Cash Flow
FY2025Q1
YoY :
-4.53%
66.43
Gross Profit Margin - %
FY2025Q1
YoY :
+4.40%
22.80
FCF Margin - %
FY2025Q1
YoY :
+230.09%
50.24
Net Margin - %
FY2025Q1
19.21
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
3.2M
USD
3
6-9
Months
0.0
USD
0
0-12
Months
930.1K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
147.2K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
557.5K
Volume
41
6-9
Months
0.0
Volume
0
0-12
Months
2.8M
Volume
87
Bought
0-3
0
0.0
Volume
Months
3-6
27
2.4M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
60
6.5M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
215.0K
USD
6
3-6
Months
366.0K
USD
4
6-9
Months
40.5K
USD
2
0-12
Months
105.5K
USD
4
Bought
0-3
8
162.0K
USD
Months
3-6
14
161.0K
USD
Months
6-9
6
48.0K
USD
Months
0-12
6
72.5K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
3.2M
USD
3
6-9
Months
0.0
USD
0
0-12
Months
930.1K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
147.2K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
JNJ News & Events
Events Timeline
2025-05-06 (ET)
2025-05-06
13:35:55
FDA announces expanded use of unannounced inspections at foreign facilities


2025-05-05 (ET)
2025-05-05
15:13:10
Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says


2025-05-05
09:13:30
Trump urges drugmakers to accept lower prices on prescriptions, Bloomberg says


Sign Up For More Events
Sign Up For More Events
News
9.0
05-05NewsfilterPinnedTREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
9.0
05-05NASDAQ.COMPinnedJ&J Reports Positive Data From Long-term Extension Study Of TREMFYA In Ulcerative Colitis
9.0
05-05NASDAQ.COMPinnedJohnson & Johnson Reports Positive Phase 3 ASTRO Study Data For TREMFYA In Ulcerative Colitis
Sign Up For More News
People Also Watch

HRTG
Heritage Insurance Holdings Inc
24.300
USD
+22.54%

KLTR
Kaltura Inc
2.200
USD
-0.45%

HCAT
Health Catalyst Inc
3.970
USD
-2.46%

NEWT
NewtekOne Inc
9.910
USD
+3.88%

SEG
Seaport Entertainment Group Inc
18.830
USD
-1.77%

GIG
GigCapital7 Corp
10.240
USD
0.00%

CERS
Cerus Corp
1.300
USD
+4.00%

PMTS
CPI Card Group Inc
20.180
USD
-20.36%

SES
SES AI Corp
0.823
USD
+1.73%

IHRT
iHeartMedia Inc
1.100
USD
+0.92%
FAQ

What is Johnson & Johnson (JNJ) stock price today?
The current price of JNJ is 157.3 USD — it has increased 1.83 % in the last trading day.

What is Johnson & Johnson (JNJ)'s business?

What is the price predicton of JNJ Stock?

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Johnson & Johnson (JNJ)'s fundamentals?

How many employees does Johnson & Johnson (JNJ). have?
